摘要
目的 评价中药方内服治疗活动期或(和)中重度甲状腺相关眼病(TAO)的疗效和安全性。方法 检索PubMed、Embase、Cochrane Library、中国知网、万方、维普、中国生物医学文献数据库自建库至2021年1月关于中药内服治疗活动期或(和)中重度TAO的文献。使用Cochrane评价工具进行质量评价,RevMan 5.4软件进行Meta分析。结果 共纳入8项研究,465例患者。与无中药方内服干预的对照组相比,治疗组在降低眼球突出度[WMD=-1.25,95%CI(-1.56,-0.95),Z=8.11,P=0.000]、临床活动性评分(CAS)[WMD=-1.00,95%CI(-1.50,-0.50),Z=3.90,P=0.000]、甲状腺相关眼病眼部病变分级(NOSPECS)[WMD=-0.58,95%CI(-0.87,-0.30),Z=3.98,P=0.000]方面均优于对照组,差异均有统计学意义。但在安全性方面证据不足,暂未见明显差异。结论 中药方内服在干预活动期或(和)中重度TAO患者的眼球突出度、CAS评分及NOSPECS分级方面有效。
OBJECTIVE To assess the efficacy and safety of Chinese medical formulae on active or(and) moderate-to-severe thyroid associated ophthalmopathy(TAO).METHODS Retrieval of medical literature involving active or(and) moderate-to-severe TAO by Chinese medical formulae was electronically performed in the following seven databases: PubMed,Embase, Cochrane library, CNKI, Wanfang database, VIP, SinoMed. All searches ended at January 2021. Quality of these researches was evaluated using tools recommended by Cochrane.We analyzed the data using RevMan 5.4.RESULTSEight RCTs with 465 participants were included. Compared with the control group(without Chinese medicine intervention), the experimental group(with Chinese medicine intervention) showed better effects of improving exophthalmos [WMD=-1.25, 95%CI(-1.56,-0.95), Z=8.11, P=0.000], clinical activity score(CAS) [WMD=-1.00, 95%CI(-1.50,-0.50), Z=3.90, P=0.000] and NOSPECS grade [WMD=-0.58,95%CI(-0.87,-0.30), Z=3.98, P=0.000], and the differences were all significant. However, the difference in safety between the control group and the experimental group showed no significance due to the absence of proof.CONCLUSIONSThis systematic review showed that Chinese medical formulae were effective in management of active or(and) moderate-to-severe TAO in terms of exophthalmos, CAS and NOSPECS grade.
作者
张翠冰
颜莹
姜泓旭
赵玲
ZHANG Cuibing;YAN Ying;JIANG Hongxu;ZHAO Ling(Yuexiu District Hospital of Traditional Chinese Medicine,Guangzhou 510030,China)
出处
《中国中医眼科杂志》
2022年第11期915-920,共6页
China Journal of Chinese Ophthalmology
基金
广东省中医院名中医药专家(吕仁和)学术经验传承工作室项目(Y0054.E54101)
2022年江西中医药大学校级大学生创新创业训练计划项目(202210412163)。
关键词
甲状腺相关眼病
中药
META分析
疗效
安全性
thyroid associated ophthalmopathy
Chinese medicine
meta-analysis
efficacy
safety
